NEWS
Our Latest News
ARCHIMED acquires SeqCenter, a fast-growing player in cutting-edge DNA and RNA gene sequencing
SeqCenter is a category leader in Next-Generation Sequencing, which can sequence hundreds of thousands of genes in record-time and at low cost.
Global private equity healthcare specialist ARCHIMED announces the acquisition of Pittsburgh, Pennsylvania-based genetic sequencing provider SeqCenter. SeqCenter’s founding scientists initially worked at the University of Pittsburgh. Frustrated with the pace, cost and difficulty of obtaining sequencing data from existing vendors and academic core laboratories, they developed their own approach to gene sequencing, ultimately leaving academia and founding SeqCenter in 2019.
Provepharm Life Solutions forms alliance with new strategic partners, ARCHIMED and Téthys Invest
April
23,
2018
Citieffe announces its first Distal Radius Plate clinical case
December
18,
2017
ARCHIMED raises €315m for second fund
September
20,
2017
Healthcare Focused Private Equity Firm ARCHIMED Closes Second Fund, at €315M
September
18,
2017
Healthcare-focused private equity firm ARCHIMED has raised a €315m fund in just four months
September
18,
2017
ARCHIMED récolte 315 M€ pour son 2ème véhicule
September
18,
2017
368